PrintThe Burrill Report
The Burrill Report (March 18, 2013): Why VC Investment in Emerging Markets Is a Demand Problem (.MP3,13.18 Mb)
A recent study published in Nature Biotechnology looks at the sources and capital flows in innovative life sciences investment in key emerging markets over the past decade. It found that contrary to popular perception, venture investment in these countries is relatively modest and that the problem is not one of supply, but demand. We spoke to Justin Chakma, analyst with Thomas, McNerney & Partners and one of the authors of the study, about some of its surprising findings, the role governments are playing to fund the sector, and what strategies venture investors can take to enter these markets.
March 14, 2013
http://www.burrillreport.com/article-why_vc_investment_in_emerging_markets_is_a_demand_problem.html
VENTURE CAPITAL
Why VC Investment in Emerging Markets Is a Demand Problem
Podcast: March 18, 2013[Please login to post comments]
- PhRMA Cheers Progress in Biotech
Report cites more than 900 biologic therapies and vaccines in development. Read More - Drug Companies Sue EMA over Trials Data
AbbVie and InteMune seek to head off release of proprietary data by regulator. Read More - Application of Nanoparticles Moves From Lab to Field
Rapid detection of deadly food-borne bacteria is made possible with a modified glucose monitoring device. Read More - Initiative Expanded to Advance Translational Research
Clinicians and researchers team up to bring novel therapies to patients faster. Read More - U.K. Regulator Finds Man Guilty of Falsifying Preclinical Data
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - FDA Proposes to Lower Bar for New Alzheimer’s Drugs
Proposed rules could speed approval of drugs that might slow or prevent the disease. Read More - High Profile Pay Cuts Reflect Move to Pay-For Performance
Private company CEOs see compensation rise as war for talent heats up. Read More - Shire Acquires Premacure
Deal adds to Shire’s late stage rare disease drug pipeline. Read More - The March 2013 Issue of
The Burrill Report
Read More - A Proof-of-Concept for Fast Exit Strategy
Podcast: March 11, 2013 Read More
.gif)
